85
Views
23
CrossRef citations to date
0
Altmetric
Anticancer Chemotherapy

Vitamin C Enhances Chemosensitization of Esophageal Cancer Cells in Vitro

Pages 539-549 | Published online: 18 Jul 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Behnaz Abiri & Mohammadreza Vafa. (2021) Vitamin C and Cancer: The Role of Vitamin C in Disease Progression and Quality of Life in Cancer Patients. Nutrition and Cancer 73:8, pages 1282-1292.
Read now
Halide S Akbas, Mujgan Timur & Tomris Ozben. (2006) Concurrent use of antioxidants in cancer therapy: an update. Expert Review of Clinical Immunology 2:6, pages 931-939.
Read now

Articles from other publishers (21)

Ali Mussa, Ros Akmal Mohd Idris, Naveed Ahmed, Suhana Ahmad, Ahmad Hafiz Murtadha, Tengku Ahmad Damitri Al Astani Tengku Din, Chan Yean Yean, Wan Faiziah Wan Abdul Rahman, Norhafiza Mat Lazim, Vuk Uskoković, Khalid Hajissa, Noor Fatmawati Mokhtar, Rohimah Mohamud & Rosline Hassan. (2022) High-Dose Vitamin C for Cancer Therapy. Pharmaceuticals 15:6, pages 711.
Crossref
Luksana ChaiswingWilliam H. St. ClairDaret K. St. Clair. (2018) Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer. Antioxidants & Redox Signaling 29:13, pages 1237-1272.
Crossref
Valeska Helfinger & Katrin Schröder. (2018) Redox control in cancer development and progression. Molecular Aspects of Medicine 63, pages 88-98.
Crossref
Ana S. Pires, Cláudia R. Marques, João C. Encarnação, Ana M. Abrantes, Inês A. Marques, Mafalda Laranjo, Rui Oliveira, João E. Casalta-Lopes, Ana C. Gonçalves, Ana B. Sarmento-Ribeiro & Maria F. Botelho. (2018) Ascorbic Acid Chemosensitizes Colorectal Cancer Cells and Synergistically Inhibits Tumor Growth. Frontiers in Physiology 9.
Crossref
Sehamuddin Galadari, Anees Rahman, Siraj Pallichankandy & Faisal Thayyullathil. (2017) Reactive oxygen species and cancer paradox: To promote or to suppress?. Free Radical Biology and Medicine 104, pages 144-164.
Crossref
Peter Bober, Michal Alexovic, Ivan Talian, Zuzana Tomkova, Zuzana Viscorova, Maria Benckova, Igor Andrasina, Rachele Ciccocioppo, Daniel Petrovic, Mariusz Adamek, Peter Kruzliak & Jan Sabo. (2016) Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line. Journal of Cancer Research and Clinical Oncology 143:1, pages 35-42.
Crossref
Sascha Venturelli, Tobias W. Sinnberg, Heike Niessner & Christian Busch. (2015) Molecular mechanisms of pharmacological doses of ascorbate on cancer cellsÜber die molekularen Wirkmechanismen pharmakologischer Dosierungen von Vitamin C gegenüber Tumorzellen. Wiener Medizinische Wochenschrift 165:11-12, pages 251-257.
Crossref
Bobae LeeSeung-Won OhSeung-Kwon Myung. (2015) Efficacy of Vitamin C Supplements in Prevention of Cancer: A Meta-Analysis of Randomized Controlled Trials. Korean Journal of Family Medicine 36:6, pages 278.
Crossref
Heidi Fritz, Gillian Flower, Laura Weeks, Kieran Cooley, Michael Callachan, Jessie McGowan, Becky Skidmore, Leesa Kirchner & Dugald Seely. (2014) Intravenous Vitamin C and Cancer. Integrative Cancer Therapies 13:4, pages 280-300.
Crossref
Renata Kontek, Marta Jakubczak & Ksenia Matlawska-Wasowska. (2014) The antioxidants, vitamin A and E but not vitamin C and melatonin enhance the proapoptotic effects of irinotecan in cancer cells in vitro. Toxicology in Vitro 28:2, pages 282-291.
Crossref
Weihua Tian, Yu Wang, Yan Xu, Xiangpeng Guo, Bo Wang, Li Sun, Longqi Liu, Fenggong Cui, Qiang Zhuang, Xichen Bao, Gunnar Schley, Tung-Liang Chung, Andrew L. Laslett, Carsten Willam, Baoming Qin, Patrick H. Maxwell & Miguel A. Esteban. (2014) The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity. Journal of Biological Chemistry 289:6, pages 3339-3351.
Crossref
Michael J. Gonzalez & Jorge R. Miranda-MassariMichael J. Gonzalez & Jorge R. Miranda-Massari. 2014. New Insights on Vitamin C and Cancer. New Insights on Vitamin C and Cancer 27 55 .
Nermi L. ParrowJonathan A. LeshinMark Levine. (2013) Parenteral Ascorbate As a Cancer Therapeutic: A Reassessment Based on Pharmacokinetics. Antioxidants & Redox Signaling 19:17, pages 2141-2156.
Crossref
Kham R.M. Martha, Gabriel Rosangkima, Longchar Amenla, Thengtom Rongpi & Surya B. Prasad. (2011) Cisplatin‐ and dietary ascorbic acid‐mediated changes in the mitochondria of Dalton’s lymphoma‐bearing mice. Fundamental & Clinical Pharmacology 27:3, pages 329-338.
Crossref
Jin-Hee Park, Keith R. Davis, Gunsup Lee, Manyong Jung, Yuchul Jung, Jungan Park, Sang-Yeop Yi, Myung-Ah Lee, Sukchan Lee, Chang-Hwan Yeom & Jin Kim. (2012) Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice. Nutrition Research 32:11, pages 873-883.
Crossref
Anja Frömberg, Daniela Gutsch, Daniel Schulze, Claudia Vollbracht, Gabriele Weiss, Frank Czubayko & Achim Aigner. (2010) Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemotherapy and Pharmacology 67:5, pages 1157-1166.
Crossref
Julien Verrax & Pedro Buc Calderon. (2009) Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radical Biology and Medicine 47:1, pages 32-40.
Crossref
Mohamed M.M. Abdel-Latif, Dermot Kelleher & John V. Reynolds. (2009) Potential Role of NF-κB in Esophageal Adenocarcinoma: As an Emerging Molecular Target. Journal of Surgical Research 153:1, pages 172-180.
Crossref
L.J. Hoffer, M. Levine, S. Assouline, D. Melnychuk, S.J. Padayatty, K. Rosadiuk, C. Rousseau, L. Robitaille & W.H. MillerJrJr. (2008) Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of Oncology 19:11, pages 1969-1974.
Crossref
David J. Stewart. (2007) Mechanisms of resistance to cisplatin and carboplatin. Critical Reviews in Oncology/Hematology 63:1, pages 12-31.
Crossref
Dugald Seely, Diana Stempak & Sylvain Baruchel. (2007) A Strategy for Controlling Potential Interactions Between Natural Health Products and Chemotherapy. Journal of Pediatric Hematology/Oncology 29:1, pages 32-47.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.